

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/543,078	07/21/2005	Michinori Kohara	382.1047	7140
23280 DAVIDSON, I	7590 06/27/2007 DAVIDSON & KAPPEL, I	EXAMINER		
485 SEVENTH AVENUE, 14TH FLOOR NEW YORK, NY 10018			PITRAK, JENNIFER S	
NEW YORK,	NY 10018		ART UNIT	PAPER NUMBER
		•	1609	•
•		•		
			MAIL DATE	DELIVERY MODE
			06/27/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	•
·\	10/543,078	KOHARA ET AL.	
Office Action Summary	Examiner	Art Unit	
	Jennifer Pitrak	1609	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with	the correspondence addres	is
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICA 36(a). In no event, however, may a rep vill apply and will expire SIX (6) MONTH, cause the application to become ABAR	ATION. y be timely filed S from the mailing date of this community S from the Mailing date of this community S (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on <u>31 Octoor</u> 2a) This action is FINAL . 2b) This 3) Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matter	• •	rits is
Disposition of Claims			
4) Claim(s) 1-17 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-17 are subject to restriction and/or expectation a	vn from consideration. election requirement.		
10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction	drawing(s) be held in abeyance	e. See 37 CFR 1.85(a).	121(d)
11) The oath or declaration is objected to by the Ex			
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Apr ity documents have been re i (PCT Rule 17.2(a)).	elication No ceived in this National Stag	je
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date		Mail Date rmal Patent Application	

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-12, and 14-16, drawn to an oligoribonucleotide or peptide nucleic acid, which binds to the RNA of a hepatitis C virus (HCV), and vectors and therapeutic agents thereof. Election of this group requires the further election of a single sequence for reasons described below.

Group II, claim(s) 13 and 17, drawn to a method of inhibiting HCV replication ability using the oligoribonucleotide or peptide nucleic acid of claims 1 and 9. Election of this group requires the further election of a single sequence for reasons described below.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature uniting groups I and II, a nucleic acid molecule complementary to HCV RNA, does not make a contribution over the prior art as evidenced by Wakita, et al. (1999. Antiviral Effects of Antisense RNA on Hepatitis C Virus RNA Translation and Expression, J. of Med. Virol., v.57:214-222.)

Sequences

Upon election of either **group I or group II**, applicant is further required to elect a single sequence for prosecution on the merits. Restriction is required under 35 U.S.C. 121 and 372, because claims 7 and 9 specifically claims numerous SEQ ID NOS.

This international searching authority considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2, and 13.3) for the reasons indicated below:

According to the guidelines in Section (f)(i)(a) of Annex B of the PCT Administrative Instructions, the special technical feature as defined by PCT Rule 13.2 shall be considered to be met when all the alternatives of a Markush-group are of similar nature. For chemical alternatives, such as the claimed sequences, the Markush group shall be regarded as being of similar nature when

- (A) all alternatives have a common property or activity and
- (B)(1) a common structure is present, i.e., a significant structure is shared by all of the alternatives or
- (B)(2) in cases where the common structure cannot be the unifying criteria, all alternatives belong to an art-recognized class of compounds in the art to which the invention pertains.

The instant sequences are considered to be each separate invention for the following reasons:

The sequences do not meet the criteria of (A), common property or activity or (B)(2), art recognized class of compounds. The sequences each behave in a different way in the context of

the claimed invention. Each member of the class cannot be substituted, one for the other, with the expectation that the same intended result would be achieved.

Further, the sequences do not meet the criteria of (B)(1), as they do not share, one with another, and a common core structure. Accordingly, unity of invention between the antisense sequences is lacking and each sequence claimed is considered to constitute a special technical feature. Applicants are directed to elect a single sequence for examination.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Requirement to elect

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the

inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Joint Inventorship Considerations

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Closing

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Pitrak whose telephone number is 571-270-3061. The examiner can normally be reached on Monday-Thursday, 7:30AM-5:00PM, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mary Mosher can be reached on 571-272-0906. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Application/Control Number: 10/543,078

Art Unit: 1609

Page 6

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Tracy Vivlemore/ Examiner, Art Unit 1635

MARY MOSHÉR SUPERVISORY PATENT EXAMINER